About
From the beginning of his neurology studies at the University of Toulouse, Dr. Pierre-Jean Ousset directed to the field of dementia and Alzheimer's disease. Initially trained in neuropsychology, he worked in the Gerontopole team alongside Prof. Bruno Vellas, helping to set up care and research structures on neurodegenerative diseases. Currently in charge of the Gerontopole Clinical Research Center, he is involved as Investigator, Principal Investigator or National Coordinator in all clinical trials for the treatment or prevention of dementia and cognitive decline.
Dr. Ousset is an active member of the European Alzheimer's Disease Consortium, member of the scientific committees of the GUIDAGE study and MAPT study (5-year placebo controlled prevention trial of omega 3 fatty acids associated with multidomain intervention). He is also a member of the scientific committee of MEMENTO-cohort in the frame of French National Alzheimer Plan.
Dr. Ousset is currently the Coordinator of the French Network for Clinical Trials in AD and is co-National Lead of the EPAD-consortium (National Coordinating Center).
As an investigator Dr. Ousset received research grants from:
Acadia Pharmaceuticals, Alzheon Inc., Araclon Biotech S.L., AstraZeneca, Biogen, Avanir Pharmaceuticals, Cortexyme Inc., Eisai Inc., Eli Lilly, Genentech, Inc., Hoffmann-La Roche, Janssen Research & Development, Merck Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk, Shanghai Greenvalley Pharmaceutical Co., TauRx Therapeutics Ltd, UCB Biopharma.
No personal advantage is to declare.